Search results
Added:
2 months ago
Source:
Radcliffe CVRM
With the rising prevalence of obesity and associated cardiovascular-kidney-metabolic (CKM) syndrome, indications for novel therapies are expanding. A new study has quantified the proportion of US adults who meet the approved indications for three key classes of CKM medications, revealing a substantial number are eligible for treatment.¹MethodologyThis cross-sectional study analysed data from…
View more
Added:
4 weeks ago
Source:
Radcliffe CVRM
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are known to reduce major atherosclerotic cardiovascular events, but the full extent of their mechanisms is still being explored. The SEMA-VR CardioLink-15 trial investigated whether semaglutide affects the levels of circulating vascular regenerative (VR) cells, which are involved in vessel repair and may modulate atherothrombotic risk.¹…
View more
Added:
5 months ago
Source:
Radcliffe Cardiology
Natriuretic peptides are key biomarkers used to risk-stratify patients with heart failure (HF), but current guideline thresholds do not typically account for body mass index (BMI).¹ A new pooled analysis suggests that these fixed thresholds may underestimate risk in patients with HF and higher BMI, questioning the one-size-fits-all approach.²This study was a participant-level pooled analysis of…
View more
Added:
4 months ago
Source:
Radcliffe CVRM
While obesity is a known risk factor for premature cardiovascular ageing, the specific impact of body fat distribution has been less clear. A new study analysing data from the UK Biobank suggests that where fat is stored has a significant, and sometimes sex-specific, influence on the biological age of the cardiovascular system.¹This cross-sectional study analysed data from 21,241 participants in…
View more
UPDATE Trial: Minimally Processed Diet Superior for Weight Loss Within Healthy Eating Guidelines
Added:
8 months ago
Source:
Radcliffe CVRM
News
Added:
11 months ago
Source:
Radcliffe CVRM
AUTHOR: Ola WisniewskaSodium-glucose cotransporter-2 (SGLT2) inhibitors significantly slow kidney function decline in patients with type 2 diabetes, with even greater benefits seen in those with higher body mass index (BMI), according to a nationwide Japanese study published recently.1Researchers analyzed data from 2,165 patients prescribed SGLT2 inhibitors compared with 4,330 matched patients on…
View more
Added:
1 year ago
Source:
Radcliffe CVRM
AUTHOR: David RamseyA new study published in Nature Medicine has provided the most extensive evaluation of the health effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs). Widely prescribed for diabetes and obesity, these medications have now been linked to a reduced risk of neurocognitive disorders, cardiovascular disease, and psychiatric conditions. However, researchers also…
View more
Added:
4 months ago
Source:
Radcliffe CVRM
The glucagon-like peptide 1 (GLP-1) receptor agonist liraglutide did not meet its primary endpoint for changing cerebral glucose metabolism but did show a beneficial effect on a secondary cognitive outcome in patients with mild to moderate Alzheimer's disease (AD), according to results from the phase 2b ELAD trial.¹Liraglutide is a GLP-1 receptor agonist approved for the treatment of type 2…
View more
Added:
9 months ago
Source:
Radcliffe CVRM
Five classic risk factors are responsible for about half of the global cardiovascular disease (CVD) burden. A major new analysis from the Global Cardiovascular Risk Consortium, published in the New England Journal of Medicine, has quantified the profound impact of these factors on lifetime estimates of CVD and all-cause mortality, revealing that their absence at midlife is associated with more…
View more
Added:
2 months ago
Source:
Radcliffe CVRM
The human metabolome reflects a complex interplay of genetic and environmental factors. A large-scale analysis integrating blood metabolomic, genomic, and lifestyle data from ten prospective cohorts has identified a comprehensive profile of circulating metabolites that are associated with the future risk of developing type 2 diabetes (T2D).¹MethodologyResearchers conducted a pooled analysis of 23…
View more